|
|
European Fine Chemicals Markets - Investment Analysis and Growth OpportunitiesPublished by: Frost & Sullivan Published: Jul. 26, 2006 Table of Contents1. Executive Summary AbstractResearch OverviewThis Frost & Sullivan research service titled European Fine Chemicals Market - Investment Analysis & Growth Opportunities provides financial benchmarking analysis of the biometrics industry - ratio analysis, year-to-date performance of Frost & Sullivan biometrics stocks and valuation multiples for biometric companies. It includes a growth monitor that ranks companies based on prospective revenue growth, and industry growth outlook that discusses market estimates until 2008. In this research service, Frost & Sullivan's expert analysts thoroughly examine the following markets: pharmaceutical intermediates, active pharmaceutical ingredients, contract biopharma, agrochemical intermediates. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
Upswing in Market for European Pharmaceutical Fine Chemical Companies, Consolidate for Success< Prospects are bright for the European fine chemicals market due to the restructuring efforts of pharmaceutical companies, increased capacity utilization rates by fine chemicals manufacturers, and the market’s focus on niche areas. In recent years, the market has faced fierce competition from Asian companies, particularly Indian and Chinese. However, since 2005, the industry has overcome slow drug approval rates, overcapacity in the market, as well as pricing pressures. Declining profits and stagnant demand have been driving fine chemical companies to consolidate to reduce competition, marketing costs, and gain better economies of scale. Moreover, to benefit from the restructuring efforts of pharmaceuticals, it is necessary for fine chemical companies to have critical mass. Hence, the market has undervalued the stocks offering attractive valuations for potential mergers and acquisitions. Increasing direct investment by Asian companies in the European market is also propelling consolidation. "Europe is seen as a launch pad into the U.S. market and this is also a positive sign for private equity participants and a good exit option as consolidation continues," states the analyst of this research service. Look Beyond Technology, Focus on Niche Markets In the next few years, European companies need to go beyond technology and become a service provider for the pharmaceuticals industry. The focus is likely to be on services, which involves more guidance and consulting. "Industry experts are optimistic about the future, as there is a slew of new project bookings and downsizing by the fine chemical market participants," says the analyst. European companies can exploit the high-value niche markets where competition from Asian companies is expected to be minimal. Focus on segments such as High Potency Active Pharmaceutical Ingredients (HPAPI), hazardous chemistry, azide chemistry market, and nano particle processing could be beneficial. Currently, the contract biopharma segment is poised to grow rapidly because of a promising pipeline of biopharmaceutical drugs that may enter the market due to the increased venture capitalist involvement. Greater investment in research and development (R&D) in the mature agrochemical intermediates segment is also likely to bring about growth. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||